Treatment of Recurrent Corneal Epithelial Defect by Autologous Serum Eye Drop
Novelty in Biomedicine,
Vol. 3 No. 1 (2015),
1 February 2015
,
Page 30-32
https://doi.org/10.22037/nbm.v3i1.7860
Abstract
Background: The aim of the present study was to evaluate the efficacy of autologous serum eye drop in treatment of recurrent corneal epithelial defect.Materials and Methods: Fourteen patients with recurrent corneal epithelial defect were studied. Autologous serum was prepared from the patients and diluted in 20% normal saline. The patients were instructed to use the autologous serum every six hours. Patients were followed for a mean period of 18 months.
Results: Four males (28.6%) and 10 females (71.4%) entered the study. Four patients stopped the treatment after three months with complete satisfaction from treatment. Patients reported a reduction in frequency and severity of attacks 4.6±2 weeks after the start of treatment. The mean number of attacks before the procedure was 7.6±0.9 per year which was reduced to 2.2±0.9 per year after treatment (p<0.001). The main side effects in patients were eye pruritus and redness which were well tolerated by patients.
Conclusion: Autologous serum application seems to be a safe and effective method to treat recurrent corneal epithelial defect.
- Autologous serum
- cornea
- epithelium
- recurrent
How to Cite
References
Fraunfelder FW, Cabezas M. Treatment of recurrent corneal erosion by extended-wear bandage contact lens. Cornea. 2011;30(2):164-6.
Ewald M, Hammersmith KM. Review of diagnosis and management of recurrent erosion syndrome. Curr Opin Ophthalmol. 2009;20(4):287-91.
Tsubota K, Goto E, Fujita H, Ono M, Inoue H, Saito I et al. Treatment of dry eye by autologous serum application in sjogren,s syndrome. Br Ophthalmol. 1999;83:390-5.
Matsumoto Y, Dogru M, Goto E, Ohashi Y, Kojima T, Ishida R, Tsubota K. Autologous serum application in the treatment of neurotrophic keratopathy. Ophthalmology. 2004;111(6):1115-20.
Ogawa Y, Okamoto S, Mori T, Yamada M, Mashima Y, Watanbe R et al. Autologous serum application in the treatment of severe dry eye in patients with chronic graft- versus- host disease. Bone Marrow Transplant. 2003;31(7):579-83.
Van Setten GB, Viinikka L, Tervo T, Pesonen K, Tarkkanen A, Perheentupa J et al. Epidermal growth factor is a constant component of normal human tear fluid. Graefe,s Arch Clin component Exp Ophthalmol. 1989;227:184- 7.
Tsubota K, Goto E, Shimmura S, Shimazaki J. Treatment of persistent corneal epithelial defect by autologous serum application. Ophthalmology. 1999;106:1984-9.
Poon AC, Geerling G, Dart JK, Fraenkel GE, Daniels JT. Autologous serum eyedrops for dry eyes and epithelial defects: clinical and in vitro toxicity studies. Br Ophthalmol. 2001;85:1188-97.
Sato Y, Katajira F, Inous S, et al. Efectes of sho-hange- kabukuryo- to and Nichin- to on levels of calcitonin gene- related peptide and levels of calcitonin gene- related peptide and substance P in human plasma. Biol Bull. 2004;27:2032- 4.
Nagano T, Nakamura M, Nakata K, et al. Effects of substance P and IGF- 1 in corneal epithelial barrier function and wound healing epithelial barrier function and wond healing in a rat model of neurotrophic keratopathy. Invest Ophthalmol Vis Sic. 2003;44: 3810- 5.
Higuchi A, Shimmura S, Takeuchi T, et al. Elucidation of apoptosis induced by serum deprivation in cultured conjunctival epithelial cells. Br J Ophthalmol. 2006;90:760-4.
Pflugfelder SC. Is autologous serum a tonic for the ailing corneal epithelium? Am J Ophthalmol. 2006;142:316-7.
Reidy JJ, Paulus MP, Gona S. Recurrent erosions of the cornea: epidemiology and treatment. Cornea. 2000;19(6):767-71.
- Abstract Viewed: 566 times
- PDF Downloaded: 451 times